The genomic examination of non-Latin black veterans with prostate cancer gives key information on precision medicine

In the largest clinical study of the genomic profiling of non-Latin Black men with prostate metastatic cancer so far scientists from the Moffitt Cancer Center, University of Pennsylvania, University of California Los Angeles and veterans (VA) National Oncology Program, when both groups were equal.

The study, published, analyzed data from over 5,000 American veterans with prostate metastatic cancer, who underwent new generation sequencing in 2019–2023. It was found that while non-Latin Black Veterans had a higher indicator that can be operated immunotherapy The goals, non-Latin white veterans had more frequent changes in the androgen receptor signaling and DNA repair routes. Despite these biological differences, the results of the survival were comparable in VA conditions with equal access.

These results confirm that precise oncology can be a powerful tool to achieve fair caring for cancer. By using genomic tests to conduct the therapy selection, we can match patients with treatment based on their biology of cancer, not breed. “

Kosj Yamoah, MD, Ph.D., Elder author and chairman of the Radiation Oncology program in Moffitt

Dr. Isla Garraway, Dr. MD, author and director of research in the Urology Department at UCLA Health, emphasized the importance of implication of the study: “This study strengthen that we cannot allow historical discrepancies define contemporary care. By determining access to genomic tools.

Their key arrangements include:

• Non-Polish black veterans were much more exposed to genomic changes related to the benefits of immunotherapy, such as microsatellite instability.
• Non-Polish white veterans had higher mutation indicators in the DNA repair genes and androgen receptor axes, which can affect the response to hormonal therapies.
• Changes in the cancer suppressor gene were associated with a worse experience in both groups.
• NO biomarker It was found that it should be excluded from tests based on the race.

A diverse study group, consisting of 36% of Niehispan black veterans, is a significant improvement in inclusion compared to previous genomic studies. Scientists emphasized the importance of further expansion of access to new generation sequencing tests and assurance that groups are insufficiently represented in precise oncological studies and clinical trials.

“This study shows that when we remove barriers in care and use precision medicine, we can improve the results for all patients,” said Dr. Kara Maxwell, dr.

The research was supported by the National Cancer Institute (P30-Ca076292), Foundation Raku Prostate (PCF22CHAL02) and VA National Precision Oncology Program.